Tribe Technologies
Trending >

Correvio is fully valued, says Mackie Research

Correvio Pharma

Specialty pharmaceutical company Correvio Pharma (TSX, NASDAQ:CORV) is up 210 per cent year-to-date, but the run is over for the time being, says André Uddin of Mackie Research, who has downgraded his rating from “Speculative Buy” to “Hold.”

In early June, Correvio announced that it had received notice from the US FDA that it could resubmit its new drug application (NDA) for anti-arrhythmic drug Brinavess, an event which caused the stock to jump more than 50 per cent in trading between June 11 and June 13.

Uddin says that the stock’s had a decent run and that he is now monetizing Correvio, one of Mackie’s four top picks for 2018.

“We view this downgrade as a trading call, CORV is now above our previous valuation of $3.30 and the stock has moved up relatively quickly since the positive Brinavess announcement. We expect the stock to take a breather,” he says in a client note on Monday (all figures in US dollars).


The analyst expects CORV to generate revenue of $7.1 million and a fully diluted EPS of negative $0.24 per share. Uddin has increased his 12-month target price from $3.30 to $4.70, representing a projected return of negative two per cent at the time of publication.

Correvio will be announcing its second quarter 2018 financial results on Tuesday.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.
insta twitter facebook


Leave a Reply